1. Scrip
  2. >>Focus On Asia
  3. >>India

Wockhardt plunges in Q4 amid expected US free fall

 
• By Anju Ghangurde

Wockhardt, which continues to grapple with compliance issues at its Indian manufacturing sites, reported a slump in profits for the fourth quarter ended March 2015, though revenues inched up propped mainly by the UK and India businesses.

Wockhardt, which continues to grapple with compliance issues at its Indian manufacturing sites, reported a slump in profits for the fourth quarter ended March 2015, though revenues inched up propped mainly by the UK and India businesses.

Net profit for the quarter was down 55% to INR340m ($5.3m), but revenues increased by 4% to INR10.79bn.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.